Time‐dependent effects of hormone‐deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging
暂无分享,去创建一个
J Kurhanewicz | S J Nelson | D B Vigneron | P. Carroll | H. Hricak | J. Kurhanewicz | M. Swanson | S. Nelson | D. Vigneron | U. Mueller-Lisse | R. Males | U G Mueller-Lisse | P R Carroll | H Hricak | M G Swanson | A Bessette | R G Males | P J Wood | S Noworolski | I Barken | S. Noworolski | I. Barken | P. Wood | A. Bessette | André Bessette
[1] J Kurhanewicz,et al. The prostate: MR imaging and spectroscopy. Present and future. , 2000 .
[2] P. Bottomley. Spatial Localization in NMR Spectroscopy in Vivo , 1987, Annals of the New York Academy of Sciences.
[3] R. Franklin,et al. Testosterone regulates pyruvate dehydrogenase activity of prostate mitochondria. , 1993, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[4] C. Magi-Galluzzi,et al. Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. , 1994, Journal of clinical pathology.
[5] M. Scholz,et al. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy. , 2000, The oncologist.
[6] R. Franklin,et al. Concepts of citrate production and secretion by prostate 1. Metabolic relationships , 1991, The Prostate.
[7] R. Franklin,et al. Testosterone and prolactin stimulation of mitochondrial aconitase in pig prostate epithelial cells. , 1996, Urology.
[8] J Kurhanewicz,et al. Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. , 2000, Neoplasia.
[9] P. Carroll,et al. Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. , 1996, Urology.
[10] M. Gleave,et al. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. , 1995, Urology.
[11] C. Begg,et al. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. , 1997, British journal of urology.
[12] J Kurhanewicz,et al. Localizing prostate cancer in the presence of postbiopsy changes on MR images: role of proton MR spectroscopic imaging. , 1998, Radiology.
[13] R. Franklin,et al. Testosterone stimulates the biosynthesis of m-aconitase and citrate oxidation in prostate epithelial cells , 1995, Molecular and Cellular Endocrinology.
[14] P. Scardino,et al. Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary. , 1996, The Urologic clinics of North America.
[15] P. Carroll,et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study. , 1999, Radiology.
[16] J. Kurhanewicz,et al. Improved water and lipid suppression for 3D PRESS CSI using rf band selective inversion with gradient dephasing (basing) , 1997, Magnetic resonance in medicine.
[17] D. Siders,et al. Long-term follow-up of stages T2-T3 prostate cancer pretreated with androgen ablation therapy prior to radical prostatectomy. , 1997, Anticancer Research.
[18] M. Gleave,et al. Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer. , 1996, Seminars in urologic oncology.
[19] P. Carroll,et al. Hormonal ablation of prostatic cancer: effects on prostate morphology, tumor detection, and staging by endorectal coil MR imaging. , 1996, AJR. American journal of roentgenology.
[20] P. Carroll,et al. Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal--pelvic phased-array coils. , 1994, Radiology.
[21] J. Kurhanewicz,et al. Detection of recurrent prostate cancer after cryosurgery. , 1998, Current opinion in urology.
[22] R. Montironi,et al. Pathological changes in prostate lesions after androgen manipulation. , 1998, Journal of clinical pathology.
[23] M. Gleave,et al. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. , 1996, The Journal of urology.
[24] F. Debruyne,et al. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. , 1997, Urology.
[25] P. Carroll,et al. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. , 1996, Radiology.
[26] C. Magi-Galluzzi,et al. Apoptosis in Prostatic Adenocarcinoma following Complete Androgen Ablation , 1998, Urologia Internationalis.
[27] L. Baert,et al. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group. , 1995, The Journal of urology.
[28] C. Begg,et al. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. , 1997, Urology.
[29] P. Carroll,et al. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. , 1996, Radiology.
[30] R. Franklin,et al. Concepts of citrate production and secretion by prostate: 2. Hormonal relationships in normal and neoplastic prostate , 1991, The Prostate.
[31] D. Grignon,et al. Histologic effects of radiation therapy and total androgen blockade on prostate cancer , 1995 .
[32] H. Hricak,et al. Clinical application of BASING and spectral/spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging , 2000, Magnetic resonance in medicine.
[33] K. Taber,et al. Magnetic resonance imaging of the efficacy of specific inhibition of 5α‐reductase in canine spontaneous benign prostatic hyperplasia , 1991 .
[34] J. Epstein,et al. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. , 1999, The American journal of pathology.
[35] R. Montironi,et al. Effects of neoadjuvant androgen deprivation therapy on prostatic cancer. , 1996, European urology.
[36] J. Isaacs,et al. The biology of hormone refractory prostate cancer. Why does it develop? , 1999, The Urologic clinics of North America.
[37] S. Nelson,et al. Surface coil MR imaging of the human brain with an analytic reception profile correction , 1995, Journal of magnetic resonance imaging : JMRI.
[38] J Kurhanewicz,et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. , 1999, Radiology.